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Sepsis has high incidence and mortality rates around the world. The role of cardiac depression in myocardial dysfunction during
sepsis remains to be elucidated. This review attempts to summarize our understanding of the anatomical, histopathological, and
pathophysiological mechanisms behind cardiac dysfunction. Biomarkers to detect cardiac depression have been used to recognize
developing problems, but the actual impact of these tools remains unclear.
1.Introduction
Sepsis and sepsis-induced mortality are major health con-
cerns worldwide [1–3]. Septic shock is the most severe form
of sepsis and is one of the most signiﬁcant causes of death
among critically ill patients. It is characterized by hemo-
dynamic changes and the dysfunction of one or more or-
gans. Septic shock is a kind of distributive shock, but it can
contain components from other forms of shock, such as
hypovolemic, cardiogenic, and obstructive shock, which can
manifest in the form of profound hypovolemia, severe ca-
rdiac failure, or pulmonary arterial hypertension, respec-
tively. Cardiovascular changes are important in septic shock;
peripheral vascular dysfunction, which can result in heter-
ogeneous microcirculatory ﬂow, can frequently induce my-
ocardial depression. In this population, cardiovascular col-
lapse can increase the risk of death in sepsis as much as two
times, and myocardial depression occurs in almost 40% of
septic patients. Myocardial depression is characterized by a
cardiac output that fails to meet metabolic demands [4, 5].
In a recent, elegant study, Vieillard-Baron et al. observed a
reduced left ventricular ejection fraction (LVEF < 45%) in
60% of patients during the ﬁrst 3 days of the treatment of
septic shock. Curiously, 39% of these patients had presented
with left ventricular hypokinesia at admission, suggesting
that the development of LVEF can occur in the earliest sepsis
stage[6].Ingeneral,approximately15%ofthedeathsrelated
to septic shock are secondary to myocardial depression [5].
Myocardial dysfunction can determine whether a patient
survives. In survivors, ventricular compliance is increased
with a higher end-diastolic volume that helps maintain an
adequate stroke volume. Nonsurvivors, in contrast, are pro-
gressively unable to maintain the same stroke volume be-
cause of reduced diastolic compliance [7]. Reversible myo-
cardial depression also plays a role in survival. It is transient
in survivors, typically with a limited duration of 7 to 10
days after the onset of sepsis. As the inﬂammatory response
is attenuated, myocardial dysfunction decreases in a self-li-
miting manner. Supportive measures, such as the optimized
preload and use of inotropes, can be critical for maintaining
adequate blood ﬂow to keep tissues perfused. Wiggers de-
scribed the concept of reversible myocardial depression or
dysfunction in 1947. He postulated the existence of a myo-
cardial depressant factor responsible for myocardial dysfunc-
tion in hemorrhagic shock [8]. During the 1960s and 1970s,
experimental studies showed evidence of transient myocar-
dial dysfunction in several forms of disease, including
hemorrhagic and septic shock [9].
It was previously postulated that decreased circulating
blood volume was responsible for the reduced cardiac out-
put observed in septic shock. More recent studies demon-
stratethatthisassumptionisparticularlytruebeforeﬂuidre-
suscitation occurs, when there may be an imbalance between
continent (vessels) and inside it. After volemic restoration,
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demand and there is no recruited preload, a level of myo-
cardial depression may still occur. Recent studies have shown
that patients with septic shock who were adequately re-
suscitated typically displayed a high cardiac output and also
displayed myocardial depression in the form of a low sys-
temic resistance hemodynamic circulatory condition. It is
estimated that only 10 to 20% of patients who have myo-
cardial depression need to receive inotropic drugs [4].
2.MyocardialDepression:A Puzzle
The pathophysiology of cardiac depression is complex and
involves a multitude of factors [10]. This review on the me-
chanismsofcardiacdepressioninsepsiswillincludeanatom-
ical, histopathological, and pathomechanistic data.
Many anatomopathologic alterations have been de-
scribed in fatal cases of septic shock. In 1948, Moon de-
scribed degenerative myocardial changes in 21 patients who
developed shock due to trauma [11]. In a necropsy study,
Fernandes J´ unior et al. enrolled 10 septic shock patients and
observed the presence of interstitial myocarditis, necrotizing
vasculitis, and myocardial abscesses, demonstrating that the
heart is aﬀected by endotoxins, mediators, and sometimes
the direct action of bacteria [12]. In 1994, the same authors
published a histopathological analysis of the myocardium of
71 patients who were autopsied after meeting the morpho-
logical criteria for sepsis. The authors observed the presence
of interstitial myocarditis in 27% of the patients, bacterial
colonization in 11%, necrosis of cardiac ﬁbers in 7%, and
interstitial edema in 28%, although this last ﬁnding was not
signiﬁcantly diﬀerent from the control group [13].
3.TheFirstPieceof thePuzzle: Endotoxins
Endotoxins mediate cardiovascular changes that mimic sep-
s i si nb o t hr e s e a r c ha n i m a l s[ 14]a n dh u m a nv o l u n t e e r s[ 15].
Suﬀredini et al. evaluated the cardiovascular eﬀects of endo-
toxemia by injecting nine healthy volunteers with a bolus
dose of endotoxin. Three hours after the injection, a phys-
iological response resembling severe sepsis was observed,
characterizedbyanincreasedheartrate,highbloodﬂow,and
a reduction in systemic vascular resistance (SVR). After in-
travascular resuscitation, there was a reduction in LVEF and
LV performance. Endotoxins can contribute to myocardial
depression through interactions with the cell membrane
receptor TLR-4, and in myocardial depression, endotoxins
initiate inﬂammation through mediators such as cytokines,
nitric oxide (NO), and C5 [16]. Despite these facts, a direct
role for endotoxins in sepsis is in doubt because many
septic patients do not have detectable endotoxin levels in
their blood and because Gram-positive sepsis exists, which is
clinically similar to Gram-negative sepsis but is independent
of endotoxins [16].
4.Connectingthe Pieces:Toll-Like Receptors
An inﬂammatory immune response begins with the recog-
nition of microorganisms and is mediated by pattern recog-
nition receptors, such as the Toll-like receptor family (TLRs),
which bind to highly conserved molecules on the pathogen
called pathogen-associated molecular proteins (PAMPs).
TLRs that recognize components of the bacterial cell wall
are expressed on the cell membrane, while TLRs that
recognize nucleic acids are located within the host cell.
TLR1 recognizes Gram-positive bacteria, TLR2 recognizes
thepeptidoglycanofGram-positivebacteria,andTLR4binds
the lipopolysaccharide of Gram-negative bacilli [16, 17].
In the heart, a number of inﬁltrating and resident
immune cells express TLR4. As a consequence, the activation
of TLR4 signaling pathways may directly cause myocyte
dysfunction. Alternatively, the activation of TLR4 signaling
pathways may result in the production of various mediators
by leukocytes (interleukin-1 (IL-1) and tumor necrosis
factor-alpha (TNF-α)), which may result in cardiac impair-
ment. Both microbial and endogenous proinﬂammatory
mediators, such as bacterial endotoxin (lipopolysaccharide
(LPS)), IL-1, and TNF-α, may directly depress myocardial
contraction [18, 19]. These factors appear to be important
because mice deﬁcient in TLR4 or IRAK1 (IL-1 receptor-
associated kinases 1) are protected from LPS-induced mor-
tality and cardiac dysfunction [20]. IRAK1 is a component
of the TLR pathway, which triggers the activation of NFκB
and the transcription of proinﬂammatory cytokines and
chemokines. A recent study exposed animals to either LPS
challenge (septic shock model) or to coronary artery ligation
(myocardial ischemia (MI) model) and found that TLR4-
deﬁcient mice challenged with LPS or MI displayed reduced
cardiac function, increased myocardial levels of IL-1β and
TNF-α, and the upregulation of mRNA encoding TLR4prior
to myocardial leukocyte inﬁltration [21].
5. Coronary Flow: No Contribution for
the Puzzle
In 1986, Cunnion et al. disproved the idea that coronary
hypoperfusion and ischemic phenomena could be involved
in the myocardial dysfunction mechanism. In a study
with coronary sinus catheterization, they demonstrated that
coronary ﬂow was the same or greater in septic shock
patients when compared to normal individuals and that
the production of lactic acid was normal [22]. This result
eliminated ischemia as a major factor in sepsis-induced
cardiac dysfunction.
6. MyocardialDepressantFactor:The Key Piece
In 1947, Wiggers [8] observed the presence of a myocardial
depressant factor in an experimental model of hemorrhagic
shock. In the 1960s, many authors described similar sub-
stances responsible for myocardial depression. In the mid-
1970s, Lefer documented the existence of a myocardial
depressantfactor(MDF)inthebloodofdogsduringinduced
endotoxic shock and suggested that it was a peptide of
800 to 1,000 daltons that originated in the pancreas [23].
To demonstrate the existence of a myocardial-depressant
substance, McConn infused the coronary ostia of dogs with
the plasma of septic patients, demonstrating the presence of
twomoleculeswithdepressoractivity[24].Theﬁrstfraction,
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depressant eﬀect, whereas the second fraction, with a weight
between 1 and 10kDa, showed late depressor activity.
Subsequent studies have proposed several substances
as MDF including tumor necrosis factor-alpha (TNF-α),
interleukin-1β (IL-1β), C5a, and endotoxin. All of these
factors, except endotoxin, are intrinsic substances made by
the immune and other systems; endotoxin, however, is an
extrinsic factor released by the breakdown of Gram-negative
bacteria [25].
The main inﬂammatory mediators that contribute to
myocardial depression in sepsis include interleukins (IL-
2, IL-4, IL-6, IL-8, and IL-10), gamma interferon (IFN-
γ), TNF-α,I L - 1 β, and C5a. The action of IL-2 in septic
shock has not yet been thoroughly determined; however,
it probably mediates the release of TNF-α and IL-1. In
patients undergoing IL-2 cancer immunotherapy, myocar-
dial depression, myocarditis, and myocardial necrosis are
observed. Despite having MDF characteristics, IL-4, IL-8,
and IL-10 did not cause signiﬁcant hemodynamic changes
when injected in experimental models. Additionally, none
of these cytokines induced myocardial depression when
tested in vitro. IL-6 is more of a marker than a mediator
of sepsis, and it is a good predictor of mortality in septic
shock [26]. IFN-γ has mild depressor eﬀects when it acts in
isolation, but it acts synergistically with TNF-α,I L - 1 ,a n d
other inﬂammatory factors, enhancing their eﬀects both in
vivo and in vitro [27]. The two cytokines that show the
greatest cardiovascular eﬀects in animals and humans are
TNF-α and IL-1β. When a small quantity of endotoxin was
injected into humans, increased levels of TNF-α were noted
[16], while the administration of recombinant TNF-α in
animal models led to the appearance of fever, lactic acidosis,
hemodynamic changes, and even death [20].
The most important inﬂammatory mediators in myocar-
dial depression in sepsis are TNF-α and IL-1. In contrast to
the other cytokines mentioned previously, they were shown
to be involved in cardiac cell contraction when injected in
vitro and observed by electronic microscopy. Additionally,
TNF-α and IL-1 show the greatest cardiovascular eﬀect in
animals and humans [28]. Preincubation of live, neonatal
rat cardiomyocytes with TNF-α blocks β-adrenoceptor-
mediated increases in pulsation amplitude and mitochon-
drial oxygen consumption [29]. The administration of
recombinant TNF-α in animal models led to the appearance
of fever, lactic acidosis, hemodynamic changes, and even
death. Many studies using anti-TNF-α antibodies in humans
andotheranimalsshowedarapidimprovementincardiovas-
cularparameters,withnodecreaseinmortality[28,30].IL-1
consists of two distinct ligands (IL-1α and IL-1β) with high-
sequence homology and indistinguishable biological activ-
ities, and both are synthesized as large precursor proteins.
IL-1α remains intracellularly unless released by a dying cell,
a n di ti sk e p ti na na c t i v e ,P r o - I L - 1 α form, that is, cleaved by
calpain to generate the mature protein. In contrast, pro-IL-
1β is biologically inactive until it is enzymatically cleaved by
caspase-1 to generate the active 17.5kDa protein [31]. This
cytokine also reproduced the hemodynamic eﬀects found
in septic shock when infused into animals. TNF-α and IL-
1β depress human myocardial function, even at low doses,
both in isolation and synergistically [19]. The maximum
eﬀect of TNF-α in TNF-α-challenged dogs was observed
between 8 and 48h after treatment [14], and it induced
nitric oxide synthase (iNOS) and enhanced production of
nitric oxide (NO) in the heart. The concept of TNF-α-in-
duced cardiodepression is supported by the induction of
iNOS and the inhibition of constitutive NOS (cNOS) or en-
dothelial NOS (eNOS) at high TNF-α concentrations. This
idea is also supported by NO-independent cardiodepression
at low, pathophysiologically relevant concentrations. TNF-α
promotes the release of sphingosine and the transient sup-
pression of calcium [32]. Additionally, Finkel et al. dem-
onstrated that TNF-α, IL-6, and IL-2 inhibited the con–
traction of isolated hamster papillary muscles in a con–
centration-dependent, reversible manner. When the NO
synthase inhibitor NG-monomethyl-L-arginine (L-NMMA)
was tested, it blocked these negative inotropic eﬀects, and L-
argininereversedtheinhibitionbyL-NMMA.Theseﬁndings
demonstrate that the direct, negative, inotropic eﬀects of
cytokines are mediated through myocardial nitric oxide
synthase [33].
C5a, a protein fragment released from the complement
component C5, has also been of interest in the pathogenesis
of sepsis-induced cardiac depression. In a rat model of sep-
sis, in vivo cardiac depression was prevented by the adminis-
tration of a blocking antibody against C5a. This experiment
also showed increased C5a receptor levels in aﬀected car-
diomyocytes, suggesting a promising approach for prevent-
ing and treating sepsis-induced cardiac depression that may
be used in future human studies [34].
7. Another Pieceof the Puzzle:
Nitric Oxide (NO)
NO is synthesized upon the cleavage of L-arginine to L-
citrulline by three distinct isoforms of NO synthase (NOS)
within the myocardium: neuronal NO synthase (NOS1),
inducible NOS (NOS2), and endothelial NOS (NOS3) [35].
NOS1 and NOS3 are constitutively expressed in cardiac
myocytes and produce NO in conjunction with myocyte
contraction due to Ca-calmodulin regulation. As discussed
previously, NO can be released by cytokine stimulation via
NOS2. This molecule is only expressed during inﬂammatory
responses and is present during many pathophysiological
conditions other than sepsis, including ischemia-reperfusion
injury and heart failure. When expressed, NOS2 produces
much higher levels of NO independent of [Ca2+]i,a s
compared to the constitutive NOS isoforms [36], and it is
an important mediator in sepsis. The impact of NO on car-
diac function is complex because it has an eﬀect on sys-
temic vascular tone, thus impacting preload, afterload, and
coronary vascular tone. NO signals through at least two dis-
tinct pathways: cyclic guanosine monophosphate- (cGMP-)
dependent and cGMP-independent pathways. The cGMP-
dependent eﬀects of NO result from the NO-induced acti-
vation of guanylate cyclase, leading to increased cGMP levels
that modulate the activity of protein kinase G (PKG) and
cGMP-regulated phosphodiesterases (PDE; cGMP stimu-
lated: PDE2; cGMP inhibited: PDE3). cGMP-independent4 Critical Care Research and Practice
eﬀects occur mainly via S-nitrosylation, an important pro-
tein modiﬁcation related to cell signaling [36]. This multifa-
ceted involvement of NO in cardiac physiology is supported
by a tight molecular regulation of the three NO synthases,
from cellular spatial conﬁnement to posttranslational allo-
steric modulation, by speciﬁc interacting proteins acting in
concert to restrict the inﬂuence of NO to a particular intra-
cellular target in a stimulus-speciﬁc manner.
NOS3 is present in endothelial cells, platelets, the brain,
and the myocardium and is dependent on calcium. In the
myocardium, NOS3 expression appears to be graded, such
that NOS3 expression in left ventricular epicardial myo-
cytes is signiﬁcantly increased compared to left ventricular
endocardial myocytes. Myocardial NOS3 may have an
important protective role against sepsis-induced myocardial
dysfunction. Experiments have shown that mice with
cardiomyocyte-speciﬁc NOS3 overexpression are protected
from myocardial dysfunction and death associated with en-
dotoxemia. Increased myocardial NO levels attenuate endo-
toxin-induced reactive oxygen species production and in-
crease total sarcoplasmic reticulum Ca2+ levels and myoﬁla-
ment sensitivity to Ca2+ [37]. In a recent study, Bougaki et al.
compared wild-type (WT) and NOS3-deﬁcient (NOS3KO)
mice submitted to severe polymicrobial sepsis induced by
colon ascendens stent peritonitis. They found that cardiac
output was markedly depressed only in NOS3KO mice
but not in WT mice. These data also suggested that NOS3
protects against systemic inﬂammation and myocardial
dysfunction after peritonitis-induced polymicrobial sepsis
in mice [38]. NOS1 is present in the central and peripheral
nervous system. Moreover, NOS1 is also constitutively ex-
pressed in cardiac myocytes. Several studies have shown
that NOS1 is capable of regulating the β-adrenergic receptor
(β-AR) pathway. In particular, in vivo and whole heart
experiments demonstrated that the knockout of NOS1 leads
to a reduced contractile response to β-AR stimulation [39].
NOS2 can be found in macrophages, neutrophils, Kupf-
fer cells, and hepatocytes, and it does not depend on
calcium. While low doses of NO may increase LV function,
excessive NO delivery from inﬂammatory cells (or cytokine-
stimulated cardiomyocytes themselves) may result in pro-
found cellular disturbances that lead to heart failure [40].
Echocardiographic examination of the cardiac function of
wild-type and NOS2-deﬁcient mice after the infusion of
endotoxin demonstrated preserved myocardial performance
in the NOS2-deﬁcient group [41]. Under normal conditions
in the vascular endothelium, NOS1 converts L-arginine into
NOviacalciumandNADPHinresponsetoendothelialstim-
ulation caused by stress or mediators of vasodilation, such as
acetylcholine, bradykinin, or histamine. NO has a short half-
life (between 6 and 10 seconds) but displays a great diﬀusion
potential. It enters the cytosol of the adjacent smooth muscle
cell where it activates soluble guanylate cyclase to produce
cGMP, which in turn promotes the sequestration of calcium
in the sarcoplasmic reticulum through L-type calcium
channels. Cytoplasmic calcium then diminishes, leading
to smooth muscle relaxation and consequent vasodilation
[33]. This process also occurs in cardiac cells, resulting in
decreasedmyocytecontraction.Balligandetal.examinedthe
interplay of bacterial endotoxin, macrophage stimulation,
NOS2, cGMP production, and reduced contractility. In this
study, rat macrophages were stimulated by exposure to LPS
and were then incubated with rat cardiomyocytes for 24h.
The amplitude of myocytes stimulated by β-agonists was
signiﬁcantly reduced in LPS-treated cells relative to controls,
and this reduction was abolished by the addition of the NOS
inhibitor L-NMMA. Additionally, LPS exposure increased
both nitrite production in myocytes and cGMP forma-
tion in ﬁbroblasts, suggesting a possible cGMP-mediated
mechanism for NO-induced negative inotropy [42]. Recent
evidence indicates that most of the cytotoxicity attributed
to NO is actually due to peroxynitrite produced from the
diﬀusion-controlled reaction between NO and another free
radical, the superoxide anion. Peroxynitrite interacts with
lipids, DNA, and proteins via direct oxidative reactions or
indirect methods and can be highly cytotoxic [43].
8.Endothelin 1
Endothelin 1 aﬀects myocardial contractile properties and
theprogression ofmyocardialhypertrophy.Elevatedconcen-
trations of ET-1 in both the plasma and myocardium have
been observed during sepsis and endotoxemia. However,
the role of elevated ET-1 during sepsis is not completely
understood. During endotoxemia, the inhibition of ET-1
biosynthesis leads to the downregulation of p38Y mitogen-
activated protein kinase (p38-MAPK) phosphorylation and
the expression of NO synthase II [27]. Sharma et al. showed
that the induction of sepsis produced a biphasic response
until 48h (elevated concentration of ET-1 at 4, 8, and 12h
returnedtobaselinevaluesat24and48h),butthisinduction
was associated with depressed myocardial performance [44].
ChopraandSharmafoundthattheelevationofET-1at3and
7 days postsepsis correlated with depressed cardiodynamics
[45].ThisresultsuggeststhattheproﬁleofET-1hasatripha-
sic response, an initial peak at 4 to 12h, and then a second
peakat3to7dayspostsepsis.BecausethesecondpeakofET-
1 is associated with depressed myocardial contractility, these
researchers speculate that the elevation of ET-1 during late
sepsis could be detrimental to myocardial function.
9. One More Piece: The Contribution of
Oxidative Stress
Reactive oxygen species (ROS) production is important for
normalcellularfunctionandsurvival.Oxidativestressresults
when ROS production and antioxidant protection mecha-
nisms are unbalanced. Endotoxins can induce superoxide
production via xanthine oxidase, NADH/NADPH oxidases,
and mitochondria. It remains unclear if the self-amplifying
cycle of ROS generation and mitochondrial damage occurs
with mitochondrial dysfunction leading to oxidative stress
and more mitochondrial impairment as the primary event,
or if oxidative stress initiates mitochondrial dysfunction and
furtherROSrelease [46]. In cardiomyocytes, ROS generation
in endotoxin-treated hearts is associated with impaired
cardiaccontractionandoxygenconsumption.Activatedneu-
trophils are the main source of ROS production, but a por-
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is derived from activated mononuclear cells. One of the key
sources of superoxide in mononuclear cells is NADH and/or
NADPH oxidase. This inducible electron transport system
transfers reducing equivalents from NADH or NADPH to
oxygen, resulting in superoxide anion (O2
−) generation, and
it is activated by endotoxins in both neutrophils and car-
diomyocytes [47]. Overproduction of prostanoids may also
be involved in the myocardial dysfunction associated with
sepsis. This overproduction occurs by the inducible isoform
of cyclooxygenase (COX-2) via activation of extracellular
signal-regulated kinases (ERK1/2), p38 kinases, and c-Jun
NH2-terminal kinases (JNK1/2/3) [48].
Oxidative stress-mediated mitochondrial damage, there-
fore, appears to be fundamental to the pathophysiology of
organ failure in sepsis, suggesting a therapeutic role for anti-
oxidants. Mitochondrial damage is mainly the result of an
inhibition of electron ﬂow through Complexes I, III, and/or
IV. Administration of a superoxide scavenger compound
prevented the mitochondrial abnormalities and improved
cardiac contractile function in an animal model of endo-
toxemia. Targeting antioxidants to mitochondria may oﬀer
a novel therapy in the future, but clearly further studies are
needed [46].
10. Autonomic Dysregulationand CalciumFlux
During sepsis, a reduction in heart rate variability is a meas-
ure of autonomic dysregulation that reﬂects a loss of the
balance between the sympathetic and vagal tone. Not only is
the reduction in heart rate variability long lasting in patients
with MODS, but also baroreﬂex sensitivity and chemoreﬂex
sensitivity are impaired. These dysfunctions correlate with
an unfavorable prognosis [49]. However, the correlation be-
tween the severity of autonomic dysfunction and the sever-
ity of septic cardiomyopathy remains unknown. Another
important observation is that levels of catecholamines are
elevated in sepsis models. There was a decreased density of
β-AR on the myocardium in a murine model of sepsis, and
this decrease was associated with a disruption of myocardial
signal transduction after β-AR stimulation that includes de-
creased levels of stimulatory G-proteins and increased ex-
pression of inhibitory G-proteins [50, 51]. This trend was
alsonotedinthemyocardiumofhumannonsurvivorsofsep-
tic shock. Zorn-Pauly et al. isolated human myocytes from
rightatrialappendagesandincubatedthemfor6to10hwith
LPS to investigate the pacemaker current If. They observed
that LPS-induced If impairment reduced the responsiveness
ofthemodelcelltoﬂuctuationsofautonomicinput,showing
a direct impact of LPS on the cardiac pacemaker current If.
This impact may contribute to the clinically observed
reduction in heart rate variability in septic patients [52].
The myocardial depression in sepsis may be attributed to a
desensitization of β-ARs due to an excess of catecholamines
and to endotoxin action on the eﬀects of the cardiac pace-
maker current If on ionic channels.
Several studies have explored calcium involvement in the
myocardial depression associated with sepsis. Calcium has
a crucial and important role in myocardial contraction. All
contractile pathways involving calcium can be connected to
myocardial dysfunction. Several studies demonstrated that
calcium has reduced peak currents during endotoxemia [53,
54]. Impaired calcium uptake, impaired release from cal-
cium sarcoplasmic reticulum storage, and decreased calcium
channel sensitivity are all involved in sepsis-related cardiac
depression [55, 56].
11. MyocardialDepressioninaClinicalView
Biomarkers such as cardiac troponin T and I have also been
studied in sepsis. Elevated cardiac troponin T and I levels
correlate with the presence of left ventricular systolic dys-
function [57]. Experimental evidence supports the view that
troponin leakage is possible even if myocardial necrosis does
not occur. Piper et al. demonstrated reversible membranous
bleb formation in rat cardiomyocytes during limited periods
ofhypoxiaandtheconcurrentreleaseofmyocardialenzymes
into the cell supernatant [58]. In addition, in a study by Ver
Elst et al., histopathologic examination revealed contraction
band necrosis in only half of patients with a positive,
premortem troponin level, and in one troponin-negative
patient, suggesting that troponin release does not necessarily
indicate myocardial cell necrosis [59]. Furthermore, levels
of cardiac troponin also correlate with the duration of
hypotension and the intensity of vasopressor support in
patients with septic shock. Turner et al. measured cardiac
troponin I levels in patients with septic shock and revealed
evidence of ongoing structural myocardial cell injury during
the course of severe sepsis and septic shock [60]. It is not
clear whether troponin I levels reveal a role for cardiac
injury in myocardial dysfunction or whether the injury is a
result of other factors, including inﬂammatory mediators or
exogenous catecholamine administration. In a study of 37
patients with septic shock, 16 (43%) patients with elevated
serum cTnI had a signiﬁcantly lower EF and a signiﬁcantly
higher mortality rate. A signiﬁcant correlation between the
serum level of cTnI and the reduction in EF was also
observed [61]. In another study of 46 patients with septic
shock, increased plasma concentrations of cTnI and cTnT
were found in 50% and 36% of patients, respectively. LV
functionalassessmentbytwo-dimensionalTOErevealedthat
both cTnI and cTnT were exclusively associated with LV
dysfunction (P<0.0001) [59]. The potential role of B-
type natriuretic peptide (BNP) as a biomarker has also been
evaluated in septic patients. Recent studies have shown an
increase in BNP levels in patients with severe sepsis and
septic shock [62, 63]. BNP levels correlate with the degree
of myocardial dysfunction and mortality. Rivers et al. found
elevated BNP levels (>230pg/mL) associated with myocar-
dial dysfunction, and severity of global tissue hypoxia. In this
population study, when adjusted for age, gender, history of
heart failure, renal function, organ dysfunction and mean
arterial pressure, a BNP greater than 210pg/mL at 24h
was the most signiﬁcant independent indicator of increased
mortality [62]. In a smaller study, Kandil et al. observed that
patientswithsepticshockhadsigniﬁcantlyhigherBNPlevels
upon admission in comparison to a control group. Indeed,
thesedatapositivelycorrelatedwithSequentialOrganFailure
Assessment scores (r2 = 0.74, P<0.05) and prognosticated6 Critical Care Research and Practice
survival [63]. Turner et al. found a relationship in surgical
septic patients between BNP levels and sepsis severity with
early systolic dysfunction, which in turn is associated with
death. In this study, a low ejection fraction (EF) (<50%)
was associated with higher BNP (by Fisher’s exact test;
P<0.05), and patients with low ejection fractions had a
higher mortality (low EF 39% versus normal EF 20%; odds
ratio = 3.03) [64]. In a recent prospective, observational,
multicenter cohort study in 10 emergency departments,
Perman et al. enrolled 825 patients to evaluate a composite
of in-hospital mortality, severe sepsis, or septic shock within
30 days following presentation. The area under the curve
(AUC) for BNP to predict the triple composite outcome was
0.69, and the optimal cutoﬀ point of BNP was 49pg/mL.
Patients with a BNP > 49pg/mL had a greater mortality
rate (P = 0.0001), a greater risk of development of severe
sepsis (P = 0.0001) and septic shock (P = 0.0001), and
a higher rate of the triple composite outcome (unadjusted
odds ratio [OR] = 1.9, 95% conﬁdence interval [CI] = 1.6 to
2.1; P<0.001). The sensitivity was 63% (95% CI = 58% to
67%), the speciﬁcity was 69% (95% CI = 65% to 73%), the
negative predictive value (NPV) was 63% (95% CI = 58% to
67%),andthepositive predictive value(PPV)was69% (95%
CI = 65% to 74%). In multivariate analysis, after adjusting
for age, gender, heart rate, white blood cell count, and
creatinine, an elevated BNP was associated with increased
odds of having a composite outcome. Outcome was similar
in patients who did not have severe sepsis or septic shock
upon arrival. BNP levels can be useful in prognosis but
have some limitations [65]. In patients with severe sepsis
and septic shock, elevated BNP levels are associated with
organ and myocardial dysfunction, global tissue hypoxia,
and mortality. All biomarkers can help in identifying high-
risk patients, but there still remains doubt as to whether
they can be utilized as organ dysfunction parameters, severe
illness criteria, or even as treatment guides. The best way to
utilizethesebiomarkersinclinicalpracticeremainsunsolved.
Bouhemad et al. performed a prospective echocardio-
graphic study to assess changesof leftventricular dimensions
over time in patients with septic shock, and they associated
those changes with troponin levels. They identiﬁed two
groups of troponin I- (cTnI-) positive septic patients whose
clinical and echocardiographic features were markedly dif-
ferent. Among patients with increased cTnI levels, patients
could be separated according to echocardiographic left sys-
tolic ventricular dysfunction or isolated impairment of left
ventricular relaxation. The concept of preload recruitment
applies exclusively to patients with systolic left ventricular
impairment, where ventricular enlargement may represent
an adaptive mechanism to maintain cardiac output. Those
patients presenting with ventricular relaxation impairment
despite showing no ventricular dilation or a drop in ejection
fraction exhibited the worst prognosis [66].
12. Treatment Options
The best treatment for myocardial dysfunction is the proper
management of sepsis. The early collection of hemocultures
in conjunction with adequate antibiotic care is the gold
standard. Moreover, aggressive ﬂuid replacement to remedy
hypovolemia, guided by the examination of ﬂuid respon-
siveness parameters, appears to be a rational strategy. This
approach aims to provide adequate perfusion, as evaluated
by central venous saturation (SvcO2) optimization and lac-
tate clearance. Keeping arterial pressure stable is very im-
portant for reestablishing organ perfusion pressure, which
helps maintain blood ﬂow to tissues. Norepinephrine is the
vasopressor of choice when a patient is nonresponsive to
ﬂuids.
Ascitedabove,only10to20%ofpatientswhohavemyo-
cardial depression will need to receive inotropic drugs to
obtain adequate tissue perfusion. Most patients will beneﬁt
from administration ﬂuid infusion. However, when inotro-
pes are indicated to optimize ﬂow and cardiac output and
improve hemodynamics, dobutamine is the ﬁrst choice. Pa-
tientsmayhaveapoorresponsetoβ-adrenergicsduetomyo-
cardial depression. In this situation, an alternative is levosi-
mendan, a calcium sensitizer, which in some clinical and ex-
perimental studies has improved perfusion [67–69]. Only
one prospective randomized controlled trial has compared
the eﬀects of levosimendan and dobutamine. This small trial
enrolled 28 septic shock patients with LV dysfunction (LVEF
< 45%) persisting after 48h of conventional treatment. The
patients were then randomized to receive a 24-h infusion of
either levosimendan (0.2μg−1·kg−1·min−1) or dobutamine
(5μg−1·kg−1·min−1). Mean arterial pressure was sustained
at approximately 70–80mmHg with norepinephrine and
volume therapy, which was guided by a Swan-Ganz catheter.
Systemic or regional hemodynamic variables were evaluated.
Although dobutamine did not alter any of the studied
parameters, levosimendan had beneﬁcial eﬀects on both car-
diovascular performance and regional perfusion. Indeed, the
use of levosimendan was associated with a reduction in LV
end-diastolic volume and a signiﬁcant increase in the stroke
index, the cardiac index, the oxygen delivery index, the oxy-
gen consumption index, and the left ventricular stroke work
index.Levosimendanalsoresultedinincreasedgastricmuco-
sal ﬂow, creatinine clearance, and urinary output and de-
creased lactate concentrations by lowering Gap PCO2 and
improving lactate clearance and SvO2 [67]. Unfortunately,
no deﬁnitive studies support levosimendan as the best
choice for patients presenting with myocardial dysfunction
by sepsis.
13. Conclusions
Many questions concerning myocardial dysfunction in sepsis
remain, spanning topics from pathomechanisms to treat-
ment. In reality, only support treatment is available for septic
patients, and no speciﬁc drugs can reverse this dysfunction.
In the future, with new approaches in sepsis treatment and
a better understanding of the mechanisms of disease, myo-
cardial dysfunction will be improved.
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